Drug Profile
Insulin inhalation - Development Center for Biotechnology
Latest Information Update: 21 Jan 2022
Price :
$50
*
At a glance
- Originator Development Center for Biotechnology
- Class Antihyperglycaemics; Hepatoprotectants; Insulins; Pancreatic hormones
- Mechanism of Action Ornithine decarboxylase stimulants; Phosphokinase stimulants; Protein tyrosine kinase stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Diabetes mellitus
Most Recent Events
- 28 Feb 2019 No recent reports of development identified for clinical-Phase-Unknown development in Diabetes-mellitus in Taiwan